Atossa Therapeutics (ATOS) Common Equity (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Common Equity of $30.5 million for Q1 2026, down 53.33% year-over-year from $65.3 million in Q1 2025, and down 22.53% quarter-over-quarter from $39.4 million in Q4 2025.
Atossa Therapeutics (ATOS) Common Equity (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Common Equity for 16 consecutive years, with $30.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 53.33% year-over-year to $30.5 million; the TTM figure through Mar 2026 stood at $30.5 million (down 53.33% YoY), while the FY2025 annual figure was $39.4 million, down 44.94% from the prior year.
- Common Equity eased to $30.5 million in Q1 2026 per ATOS's latest filing, from $39.4 million in the prior quarter.
- Across five years, Common Equity topped out at $135.2 million in Q1 2022 and bottomed at $30.5 million in Q1 2026.
- Historically, Common Equity has averaged $86.4 million across 5 years, with a median of $85.8 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity slipped 3.25% — and 2026, when it tumbled 53.33%.
- Atossa Therapeutics' Common Equity stood at $118.0 million in 2022, then dropped by 22.84% to $91.0 million in 2023, then retreated by 21.47% to $71.5 million in 2024, then plunged by 44.94% to $39.4 million in 2025, then retreated by 22.53% to $30.5 million in 2026.
- Business Quant data shows ATOS's Common Equity at $30.5 million in Q1 2026, $39.4 million in Q4 2025, and $49.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Atossa Therapeutics | 22.79 Mn | 22.79 Mn | - | 26.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.83 Mn |
| Mar 31, 2026 | 30.49 Mn |
| Dec 31, 2025 | 39.35 Mn |
| Sep 30, 2025 | 49.79 Mn |
| Jun 30, 2025 | 57.70 Mn |
| Mar 31, 2025 | 65.32 Mn |
| Dec 31, 2024 | 71.48 Mn |
| Sep 30, 2024 | 73.68 Mn |
| Jun 30, 2024 | 80.16 Mn |
| Mar 31, 2024 | 85.76 Mn |
| Dec 31, 2023 | 91.02 Mn |
| Sep 30, 2023 | 98.25 Mn |
| Jun 30, 2023 | 104.88 Mn |
| Mar 31, 2023 | 113.26 Mn |
| Dec 31, 2022 | 117.96 Mn |
| Sep 30, 2022 | 123.86 Mn |
| Jun 30, 2022 | 130.26 Mn |
| Mar 31, 2022 | 135.16 Mn |
| Dec 31, 2021 | 138.14 Mn |
| Sep 30, 2021 | 141.35 Mn |